Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
| Market Cap | $5.85B-6.5% |
| Revenue (ttm) | $450.82M-45.6% |
| Net Income | -$724.20M-44302.3% |
| EPS | -$5.09-7171.4% |
| Shares Out | 141.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,906,214 |
| Open | $43.36 |
| Previous Close | $43.65 |
| Day's Range | $41.17 - $44.71 |
| 52-Week Range | $40.43 - $95.49 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | $111.20(+168.79%) |
| Earnings Date | Feb 4, 2027 |
About ARWR
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating ARWR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 4, 2027Earnings report
$ARWR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ARWR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARWR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARWR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ARWR Revenue by Segment
| Collaboration and license revenue | $444.21M | 33.72% |
| Candidate costs | $443.22M | 33.65% |
| Acquired Priority Review Voucher | $215.00M | 16.32% |
| Professional, outside services, and other | $92.58M | 7.03% |
| Discovery costs | $78.84M | 5.99% |
| Facilities related | $31.07M | 2.36% |
| Product revenue, net | $6.60M | 0.50% |
| Other, net | $3.98M | 0.30% |
| Cost of product revenue | $1.80M | 0.14% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-K)
U.S. Patents
New ARWR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARWR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARWR
| IJHiShares Core S&P Mid-Cap ETF | $210.55M |
| VTIVanguard Morningstar Total Stock Market ETF | $201.79M |
| VBVanguard Morningstar Small-Cap ETF | $180.20M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $100.88M |
| VXFVanguard Extended Market ETF | $96.00M |
| XBIState Street SPDR S&P Biotech ETF | $80.01M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ARWR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage: REDEMPLO opportunity and commercial momentum offset by earnings miss and widening losses.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| THNR | Amplify Weight Loss Drug & Treatment ETF | 2.78% |
| HLTH | Tema Healthcare AI ETF | 2.55% |
| GNOM | Global X - Genomics & Biotechnology ETF | 1.97% |
| FRTY | Alger Mid Cap 40 ETF | 1.88% |
| RFG | Invesco S&P MidCap 400 Pure Growth ETF | 1.58% |
| XMMO | Invesco S&P MidCap Momentum ETF | 1.30% |
| TDNA | T. Rowe Price Biotech ETF | 1.24% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 1.12% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 1.05% |
| WDNA | WisdomTree BioRevolution Fund | 0.96% |
| XBI | State Street SPDR S&P Biotech ETF | 0.85% |
| BBP | Virtus Biotech ETF | 0.85% |
Weight is the stock’s share of each fund’s holdings.
